Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, announced an agreement with Nanna Therapeutics (Nanna), a small-molecule focused therapeutics biotech subsidiary of Astellas.
Terms of the Agreement
Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.
DUB enzymes
The DUB enzymes regulate ubiquitination in the ubiquitin-proteasome system (UPS). Dysregulation of DUB activity is implicated in many human diseases, highlighting their importance and promise for the development of novel therapeutics.
About Ubiquigent
- Ubiquigent is the partner chosen by many leading industry and academic organisations for their drug discovery programmes in the fields of protein degradation, stabilisation and cellular signalling.
- Ubiquigent has an established specialised drug discovery platform and long-standing expertise in the exploitation of the DUBs for therapeutic benefit.
- The platform can be applied to support the development of DUB inhibitors, DUB-targeting PROTACs, and DUBTACs across any therapeutic area.
Words from CEO: Ubiquigent
Jason Mundin, CEO of Ubiquigent, commented: “We are delighted to enter this latest agreement and look forward to supporting the team at Nanna Therapeutics. Our platform was established to support those seeking to modulate DUB activity for therapeutic benefit and has been used by a long list of global partners which we are very pleased to add Nanna Therapeutics to.”
As pioneers in the rapidly emerging deubiquitinase (DUB) space, Ubiquigent is uniquely positioned to drive forward the discovery and development of novel DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-targeting Chimeras (DUBTACs) as powerful new therapeutics for areas of high unmet need.
